Abstract:Introduction: CXCL17 is a mucosally secreted protein, and the most recently identified human chemokine, an assignment based on protein fold prediction and chemotactic activity for leukocytes. However, these credentials have been the subject of much recent discussion and no experimental evidence has been presented regarding the definitive structure of CXCL17. In this study, we evaluated the structural and chemoattractant credentials of CXCL17 to better characterize this molecule, and gain deeper insights into its functional role as a glycosaminoglycan (GAG) binding protein. Methods: In the absence of structural information, in silico modeling techniques assessed the likelihood of CXCL17 adopting a chemokine fold. Recombinant CXCL17 was synthesized in mammalian and prokaryotic systems. Modified Boyden chamber and real-time chemotaxis assays assessed the ability of CXCL17 to promote chemotaxis of murine splenocytes, human neutrophils, and CXCR1 transfectants. The efficacy of CXCL17 binding to GAGs was quantified with solid-phase assays and bio-layer interferometry techniques. Results: All modeling efforts failed to support classification of CXCL17 as a chemokine based on its predicted conformation. Recombinant CXCL17 was observed to dimerize as a function of concentration, a characteristic of several chemokines. Contrary to a previous report, CXCL17 was not chemotactic for murine splenocytes, although it was a low-potency chemoattractant for human neutrophils at micromolar concentrations, several orders of magnitude higher than those required for CXCL8. As anticipated owing to its highly basic nature, CXCL17 bound to GAGs robustly, with key C-terminal motifs implicated in this process. While inactive via CXCR1, CXCL17 was found to inhibit CXCR1-mediated chemotaxis of transfectants to CXCL8 in a dose-dependent manner. Discussion: In summary, despite finding little evidence for chemokine-like structure and function, CXCL17 readily bound GAGs, and could modulate chemotactic responses to another chemokine in vitro. We postulate that such modulation is a consequence of superior GAG binding, and that C-terminal fragments of CXCL17 may serve as prototypic inhibitors of chemokine function.

ACKR5/GPR182 is a scavenger receptor for the atypical chemokine CXCL17, GPR15L and various endogenous peptides

Identification of the orphan GPR25 as a receptor of the chemokine CXCL17

The GPCR, class C, group 6, subtype A (GPRC6A) receptor: from cloning to physiological function

Structure basis of ligand recognition and activation of GPR55

Molecular recognition of the atypical chemokine-like peptide GPR15L by its cognate receptor GPR15

A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55.

Ligand entry pathways control the chemical space recognized by GPR183

CXCR7 Functions as a Scavenger for CXCL12 and CXCL11

CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signaling

Activation and Allosteric Regulation of the Orphan GPR88-Gi1 Signaling Complex.

MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs

Cryo-EM structures of orphan GPR21 signaling complexes

The orphan receptor GPR55 is a novel cannabinoid receptor

GPR39: An orphan receptor begging for ligands

Identifying the Localization and Exploring a Functional Role for Gprc5c in the Kidney.

Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias

CXCR4/ACKR3 Phosphorylation and Recruitment of Interacting Proteins: Key Mechanisms Regulating Their Functional Status

Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor

Uncovering the signalling, structure and function of the 20‐HETE‐GPR75 pairing: Identifying the chemokine CCL5 as a negative regulator of GPR75

G protein selectivity profile of GPR56/ADGRG1 and its effect on downstream effectors

Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2